Form 4: Artivion SVP, Clinical & MD Affairs, Marshall S. Stanton, Reports Acquisition of 18,398 Shares

Marshall S. Stanton, SVP, Clinical & MD Affairs at Artivion, Inc., reports acquiring 18,398 shares of common stock on February 28, 2025.

Summary

• On February 28, 2025, Marshall S. Stanton, SVP, Clinical & MD Affairs at Artivion, Inc. (AORT), acquired 18,398 shares of common stock.
• The shares were acquired at a price of $0.
• Following the transaction, Stanton directly owns 98,243 shares of Artivion, Inc.
• The acquired shares are restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of insider trading activity. The acquisition itself could be seen as slightly positive, but the filing is primarily informational.

Positives

• The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is required when an insider of a publicly traded company buys or sells the company's securities. It provides transparency into the transactions of company insiders.

Stakeholder Impact

• Shareholders may view the insider's stock purchase as a positive signal about the company's prospects.

Key Dates